

Kerry J Savage

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5189180/publications.pdf>

Version: 2024-02-01

301
papers

27,665
citations

12322

69
h-index

5986

160
g-index

302
all docs

302
docs citations

302
times ranked

22901
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
2	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
3	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2007, 109, 1857-1861.	0.6	1,193
4	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
5	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1283-1294.	5.1	818
6	The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. <i>Blood</i> , 2003, 102, 3871-3879.	0.6	793
7	ALK ⁺ anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ⁺ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2008, 111, 5496-5504.	0.6	784
8	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. <i>Blood</i> , 2005, 105, 1851-1861.	0.6	778
9	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009, 114, 3533-3537.	0.6	566
10	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
11	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , 2011, 471, 377-381.	13.7	551
12	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551
13	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1182-1189.	0.8	535
14	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , 2009, 114, 2273-2279.	0.6	523
15	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , 2019, 393, 229-240.	6.3	517
16	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	0.8	394
17	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.	0.6	376
18	Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. <i>Journal of Clinical Oncology</i> , 2013, 31, 1970-1976.	0.8	335

#	ARTICLE	IF	CITATIONS
19	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	0.8	334
20	Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5165-5169.	0.8	333
21	Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. <i>Annals of Oncology</i> , 2004, 15, 1467-1475.	0.6	314
22	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	0.8	313
23	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
24	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.	0.8	287
25	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	0.8	273
26	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. <i>Cancer Cell</i> , 2010, 18, 590-605.	7.7	263
27	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2014, 123, 2062-2065.	0.6	259
28	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	0.8	257
29	Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1741-1746.	0.8	235
30	NF κ B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. <i>Blood</i> , 2005, 106, 1392-1399.	0.6	229
31	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	7.7	213
32	Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. <i>Annals of Oncology</i> , 2006, 17, 123-130.	0.6	212
33	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1236-1243.	0.6	199
34	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	5.1	183
35	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , 2014, 46, 329-335.	9.4	180
36	Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 793-799.	0.8	178

#	ARTICLE	IF	CITATIONS
37	International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 3383-3388.	0.8	171
38	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1997-2007.	0.8	170
39	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017, 129, 2581-2584.	0.6	161
40	Acquired <i>TNFRSF14</i> Mutations in Follicular Lymphoma Are Associated with Worse Prognosis. <i>Cancer Research</i> , 2010, 70, 9166-9174.	0.4	160
41	The biology and management of systemic anaplastic large cell lymphoma. <i>Blood</i> , 2015, 126, 17-25.	0.6	157
42	Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 406-421.	7.7	155
43	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	0.6	145
44	The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. <i>Blood</i> , 2005, 105, 308-316.	0.6	141
45	Anaplastic large cell lymphoma, ALK-negative. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 206-215.	2.0	129
46	Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size. <i>Journal of Clinical Oncology</i> , 2008, 26, 5170-5174.	0.8	126
47	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
48	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	0.6	112
49	Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 2190-2199.	3.2	110
50	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2484-2492.	0.8	106
51	Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 461-469.	1.2	100
52	Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3396-3401.	0.8	99
53	Anaplastic large cell lymphoma, ALK-positive. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 293-302.	2.0	98
54	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98

#	ARTICLE	IF	CITATIONS
55	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2019, 134, 802-813.	0.6	96
56	Peripheral T-cell lymphoma " Not otherwise specified. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 321-329.	2.0	95
57	Long-term outcomes for patients with limited stage follicular lymphoma. <i>Cancer</i> , 2010, 116, 3797-3806.	2.0	94
58	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
59	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	1.3	90
60	Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1 "2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 257-266.	5.1	89
61	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86
62	Peripheral T-cell Lymphomas. <i>Blood Reviews</i> , 2007, 21, 201-216.	2.8	83
63	Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. <i>Blood</i> , 2011, 118, 4585-4590.	0.6	83
64	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2021, 8, e410-e421.	2.2	83
65	Primary Mediastinal Large B-Cell Lymphoma. <i>Oncologist</i> , 2006, 11, 488-495.	1.9	79
66	Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. <i>British Journal of Haematology</i> , 2017, 176, 210-221.	1.2	78
67	Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 106-112.	2.1	77
68	Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. <i>Blood</i> , 2019, 134, 761-764.	0.6	77
69	A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. <i>Investigational New Drugs</i> , 2008, 26, 249-255.	1.2	76
70	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. <i>Blood</i> , 2014, 123, 3567-3573.	0.6	76
71	High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. <i>Blood Advances</i> , 2018, 2, 2755-2765.	2.5	74
72	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Canadian study of 443 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1041-1046.	2.0	71

#	ARTICLE	IF	CITATIONS
73	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	1.2	71
74	Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. <i>Haematologica</i> , 2011, 96, 1002-1007.	1.7	69
75	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 195-203.	1.3	65
76	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
77	Mutational landscape of gray zone lymphoma. <i>Blood</i> , 2021, 137, 1765-1776.	0.6	60
78	Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. <i>British Journal of Haematology</i> , 2015, 169, 520-527.	1.2	58
79	Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2021, 137, 929-938.	0.6	57
80	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2493-2500.	0.8	56
81	Identification of high-risk <i>DUSP22</i> rearranged <i>ALK</i> -negative anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e28-e31.	1.2	56
82	Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. <i>Leukemia and Lymphoma</i> , 2005, 46, 1721-1727.	0.6	55
83	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	0.8	50
84	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3722-3733.	0.8	48
85	Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide. <i>Oncologist</i> , 2010, 15, 765-771.	1.9	46
86	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	0.6	46
87	Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach. <i>Blood</i> , 2020, 136, 2803-2811.	0.6	46
88	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	15.2	46
89	TRAF1 Expression and c-Rel Activation Are Useful Adjuncts in Distinguishing Classical Hodgkin Lymphoma From a Subset of Morphologically or Immunophenotypically Similar Lymphomas. <i>American Journal of Surgical Pathology</i> , 2005, 29, 196-203.	2.1	45
90	Therapies for Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 515-524.	0.9	43

#	ARTICLE	IF	CITATIONS
91	Rituximab with high-dose methotrexate in primary central nervous system lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 1149-1154.	2.0	41
92	Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types). <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 267-277.	0.9	40
93	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
94	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 341-348.	0.2	39
95	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , 2018, 131, 2036-2046.	0.6	39
96	Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 280-288.	0.9	38
97	The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: A study of 826 cases from the International Peripheral T-cell Lymphoma Project. <i>American Journal of Hematology</i> , 2012, 87, 790-794.	2.0	38
98	Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e263-e266.	0.3	38
99	ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. <i>Haematologica</i> , 2019, 104, e562-e565.	1.7	38
100	Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8507-8507.	0.8	37
101	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	1.5	36
102	Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. <i>Annals of Oncology</i> , 2013, 24, 428-432.	0.6	36
103	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1110-1110.	0.6	35
104	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016, 175, 876-883.	1.2	34
105	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 324-332.	0.6	32
106	Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 578-586.	0.9	32
107	Gene expression profiling of gray zone lymphoma. <i>Blood Advances</i> , 2020, 4, 2523-2535.	2.5	32
108	Nodular lymphocyte-predominant Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016, 53, 190-202.	1.8	30

#	ARTICLE	IF	CITATIONS
109	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies. <i>Blood Reviews</i> , 2018, 32, 249-255.	2.8	29
110	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. <i>Blood</i> , 2012, 120, 303-303.	0.6	29
111	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , 2009, 114, 408-408.	0.6	28
112	Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 394-394.	0.6	27
113	Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia. <i>Oncologist</i> , 2014, 19, 283-290.	1.9	26
114	Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. <i>British Journal of Haematology</i> , 2017, 179, 508-510.	1.2	26
115	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
116	Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017, 130, 651-651.	0.6	25
117	Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. <i>American Journal of Hematology</i> , 2006, 81, 969-972.	2.0	24
118	Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2319-2327.	0.6	23
119	Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3486-3494.	2.5	23
120	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). <i>Blood</i> , 2014, 124, 392-392.	0.6	23
121	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. <i>Blood Advances</i> , 2019, 3, 3953-3961.	2.5	22
122	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. <i>British Journal of Haematology</i> , 2017, 176, 234-240.	1.2	20
123	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. <i>Blood</i> , 2015, 126, 579-579.	0.6	20
124	Characterization of DLBCL with a PMBL gene expression signature. <i>Blood</i> , 2021, 138, 136-148.	0.6	19
125	Primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2022, 140, 955-970.	0.6	19
126	Three-Year Follow-Up Data and Characterization Of Long-Term Remissions From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4382-4382.	0.6	19

#	ARTICLE	IF	CITATIONS
127	Update on the World Health Organization classification of peripheral T-cell lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 227-235.	1.2	18
128	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015, 125, 2175-2177.	0.6	18
129	A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study. <i>Leukemia and Lymphoma</i> , 2019, 60, 912-919.	0.6	18
130	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , 2021, 137, 2196-2208.	0.6	18
131	Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). <i>Blood</i> , 2019, 134, 401-401.	0.6	18
132	The spectrum of peripheral T-cell lymphomas. <i>Current Opinion in Hematology</i> , 2009, 16, 292-298.	1.2	17
133	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. <i>Blood Advances</i> , 2021, 5, 1483-1489.	2.5	17
134	Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6039-6053.	3.2	17
135	Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. <i>Blood Advances</i> , 2022, 6, 5550-5555.	2.5	17
136	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	0.8	17
137	Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1813-1818.	2.0	16
138	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. <i>Haematologica</i> , 2018, 103, e590-e593.	1.7	16
139	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 21-23.	0.6	16
140	Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.. <i>Blood</i> , 2007, 110, 787-787.	0.6	16
141	Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL). <i>Blood</i> , 2010, 116, 113-113.	0.6	16
142	Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 189-207.	0.9	15
143	Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. <i>British Journal of Haematology</i> , 2019, 186, e24-e27.	1.2	15
144	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. <i>Blood Advances</i> , 2019, 3, 2804-2811.	2.5	15

#	ARTICLE	IF	CITATIONS
145	Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study. <i>Blood</i> , 2020, 136, 1006-1010.	0.6	15
146	An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant. <i>Blood</i> , 2019, 134, 464-464.	0.6	15
147	Defining the clonality of peripheral T cell lymphomas using RNA-seq. <i>Bioinformatics</i> , 2017, 33, 1111-1115.	1.8	14
148	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 276-282.	0.6	14
149	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. <i>Blood</i> , 2007, 110, 790-790.	0.6	14
150	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	0.6	14
151	Molecular Signatures of Lymphoma. <i>International Journal of Hematology</i> , 2004, 80, 401-409.	0.7	13
152	Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2516-2523.	0.6	13
153	Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1256-1259.	0.6	13
154	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 133-133.	0.6	13
155	Novel therapies in peripheral T-cell lymphomas. <i>Current Oncology Reports</i> , 2008, 10, 404-411.	1.8	12
156	Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma after type post-transplant lymphoproliferative disorder. <i>British Journal of Haematology</i> , 2020, 189, 97-105.	1.2	12
157	Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study. <i>Blood</i> , 2018, 132, 2897-2897.	0.6	12
158	A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1093-1093.	0.6	12
159	Update: Peripheral T-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 222-230.	1.2	11
160	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. <i>Haematologica</i> , 2016, 101, e411-e414.	1.7	11
161	Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium. <i>Blood</i> , 2013, 122, 3032-3032.	0.6	11
162	NF- κ B Activation in Primary Mediastinal Large B-Cell Lymphoma: Nuclear Localization of c-REL and Coordinate Upregulation of NF- κ B Target Genes.. <i>Blood</i> , 2004, 104, 243-243.	0.6	11

#	ARTICLE	IF	CITATIONS
163	Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them. <i>Expert Review of Hematology</i> , 2016, 9, 1007-1009.	1.0	10
164	Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 872-879.	0.6	10
165	High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 481-484.	1.3	10
166	HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S373-S374.	0.2	10
167	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 1618-1618.	0.6	10
168	Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. <i>Blood</i> , 2018, 132, 1647-1647.	0.6	10
169	Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. <i>Blood</i> , 2018, 132, 2932-2932.	0.6	10
170	PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2008, 112, 261-261.	0.6	10
171	Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017, 130, 650-650.	0.6	10
172	Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9032-9032.	0.8	10
173	Modern management of lymphocyte predominant <sc>H</sc>odgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 161, 316-329.	1.2	9
174	Validation of a simplified international prognostic score (IPS–3) in patients with advanced–stage classic Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 122-127.	1.2	9
175	Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 1466-1471.	1.7	9
176	Outcome of relapsed and refractory nodular lymphocyte–predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , 2021, 192, 560-567.	1.2	9
177	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. <i>Blood</i> , 2010, 116, 854-854.	0.6	9
178	The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 727-729.	0.6	8
179	Central Nervous System Prophylaxis for Aggressive B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1277-1291.	0.9	8
180	A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial. <i>Blood</i> , 2013, 122, 371-371.	0.6	8

#	ARTICLE	IF	CITATIONS
181	Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible. <i>Blood</i> , 2014, 124, 3069-3069.	0.6	8
182	The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 495-495.	0.6	8
183	Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 2736-2736.	0.6	8
184	Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology. <i>Blood</i> , 2021, 138, 2499-2499.	0.6	8
185	Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 711-714.	0.6	7
186	Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).. <i>Blood</i> , 2005, 106, 492-492.	0.6	7
187	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012, 120, 3701-3701.	0.6	7
188	A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results. <i>Blood</i> , 2015, 126, 3976-3976.	0.6	7
189	Long-Term Results of PET-Guided Radiation Therapy in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma Treated with R-CHOP in British Columbia. <i>Blood</i> , 2017, 130, 823-823.	0.6	7
190	Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5285-5294.	2.5	7
191	Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin. <i>Hematological Oncology</i> , 2019, 37, 35-38.	0.8	6
192	Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 4023-4023.	0.6	6
193	A Phase II Study of Enzastaurin, a Protein Kinase C- β (PKC β) Inhibitor, in the Treatment of Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2005, 106, 934-934.	0.6	6
194	The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis. <i>Blood</i> , 2012, 120, 1531-1531.	0.6	6
195	Maxillofacial lymphomas. <i>British Journal of Radiology</i> , 2021, 94, 20191041.	1.0	5
196	Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. <i>Current Oncology</i> , 2021, 28, 3537-3553.	0.9	5
197	Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is Poor with Majority Having Transformed Lymphoma. <i>Blood</i> , 2018, 132, 2873-2873.	0.6	5
198	Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia. <i>Blood</i> , 2013, 122, 1788-1788.	0.6	5

#	ARTICLE	IF	CITATIONS
199	Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4345-4345.	0.6	5
200	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 629-629.	0.6	5
201	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 703-703.	0.6	5
202	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016, 128, 2923-2923.	0.6	5
203	CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus. <i>Cancers</i> , 2022, 14, 89.	1.7	5
204	Evaluation of the discussion of late effects and screening recommendations in survivors of adolescent and young adult (AYA) lymphoma. <i>Journal of Cancer Survivorship</i> , 2021, 15, 179-189.	1.5	4
205	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <i>Blood Advances</i> , 2021, 5, 3647-3655.	2.5	4
206	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study. <i>Blood</i> , 2020, 136, 44-45.	0.6	4
207	The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.. <i>Blood</i> , 2009, 114, 1554-1554.	0.6	4
208	Long-Term Survival Analyses of an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 3689-3689.	0.6	4
209	ABVD Chemotherapy Results in Excellent Outcomes with Reduced Radiation Therapy Rates in Children, Adolescents and Young Adults with Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 2695-2695.	0.6	4
210	Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia. <i>British Journal of Haematology</i> , 2022, 198, 684-692.	1.2	4
211	Novel therapies in peripheral T-cell lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2008, 3, 213-220.	1.2	3
212	Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S52.	0.2	3
213	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.	0.6	3
214	Identification of LAG3+ T Cell Populations in the Tumor Microenvironment of Classical Hodgkin Lymphoma and B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 19-19.	0.6	3
215	Transformed Lymphoma: Incidence and Long-Term Outcome.. <i>Blood</i> , 2004, 104, 3253-3253.	0.6	3
216	FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.. <i>Blood</i> , 2007, 110, 213-213.	0.6	3

#	ARTICLE	IF	CITATIONS
217	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. Blood, 2009, 114, 133-133.	0.6	3
218	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. Blood, 2011, 118, 780-780.	0.6	3
219	Genomic Rearrangements Involving Programmed Death Ligands Are Recurrent In Primary Mediastinal Large B-Cell Lymphoma. Blood, 2013, 122, 635-635.	0.6	3
220	Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma. Blood, 2015, 126, 2699-2699.	0.6	3
221	Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma. Blood, 2013, 122, 4237-4237.	0.6	3
222	Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.. Journal of Clinical Oncology, 2022, 40, 7552-7552.	0.8	3
223	X. Challenges and future directions in peripheral Tâ€cell lymphoma. Hematological Oncology, 2015, 33, 56-61.	0.8	2
224	Keeping Our Finger on the Pulse: Reaffirming the Role of Radiation Therapy in the Curative Management of Early Stage Follicular Lymphoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 459-465.	0.4	2
225	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. Leukemia and Lymphoma, 2020, 61, 3014-3017.	0.6	2
226	Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis. Journal of Cancer Survivorship, 2021, 15, 837-846.	1.5	2
227	Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma. Journal of Nuclear Medicine, 2021, , jnumed.121.262324.	2.8	2
228	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 1560-1560.	0.6	2
229	TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP. Blood, 2019, 134, 3964-3964.	0.6	2
230	Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.. Blood, 2007, 110, 3040-3040.	0.6	2
231	Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).. Blood, 2009, 114, 1678-1678.	0.6	2
232	Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors. Blood, 2011, 118, 96-96.	0.6	2
233	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. Blood, 2013, 122, 3044-3044.	0.6	2
234	Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat. Blood, 2014, 124, 3075-3075.	0.6	2

#	ARTICLE	IF	CITATIONS
235	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	0.6	2
236	A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15. <i>Blood</i> , 2016, 128, 4162-4162.	0.6	2
237	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 135-135.	0.6	2
238	Outcomes of Stage I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. <i>Blood</i> , 2018, 132, 4148-4148.	0.6	1
239	Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray. <i>Blood</i> , 2018, 132, 348-348.	0.6	1
240	Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi-Center Phase I/II Experience. <i>Blood</i> , 2018, 132, 2907-2907.	0.6	1
241	Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach. <i>Blood</i> , 2019, 134, 2845-2845.	0.6	1
242	Molecular Profiling of Diffuse Large B-Cell Lymphoma Identifies Robust Subtypes Including One Characterized by Host Inflammatory Response.. <i>Blood</i> , 2004, 104, 25-25.	0.6	1
243	Survival of Limited Stage Peripheral T-Cell Lymphoma Is Similar To Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2817-2817.	0.6	1
244	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. <i>Blood</i> , 2014, 124, 1624-1624.	0.6	1
245	Rituximab with High Dose Methotrexate in the Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 3090-3090.	0.6	1
246	Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype. <i>Blood</i> , 2015, 126, 109-109.	0.6	1
247	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2015, 126, 3905-3905.	0.6	1
248	Survival Analysis of Anaplastic Large Cell Lymphoma, Systemic and Cutaneous-Types: Report from the International T-Cell Lymphoma Project.. <i>Blood</i> , 2006, 108, 293-293.	0.6	1
249	TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.. <i>Blood</i> , 2009, 114, 1919-1919.	0.6	1
250	Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 242-242.	0.6	1
251	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. <i>Blood</i> , 2014, 124, 2960-2960.	0.6	1
252	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. <i>Blood</i> , 2014, 124, 1630-1630.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL). <i>Blood</i> , 2015, 126, 2667-2667.	0.6	1
254	Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 607-607.	0.6	1
255	Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome. <i>Blood</i> , 2019, 134, 922-922.	0.6	1
256	Outcome of elderly patients with classical Hodgkin lymphoma (HL) in British Columbia.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8031-8031.	0.8	1
257	The impact of surveillance imaging after curative-intent radiotherapy for limited-stage follicular lymphoma. <i>British Journal of Haematology</i> , 2021, 195, 802-805.	1.2	1
258	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	1
259	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021, 138, 1326-1326.	0.6	1
260	Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT). <i>Blood</i> , 2021, 138, 624-624.	0.6	1
261	244 Long-Term Outcomes for Patients with Limited Stage Follicular Lymphoma: An Update of the BC Cancer Experience. <i>Radiotherapy and Oncology</i> , 2019, 139, S101-S102.	0.3	0
262	Is the CNS-PINK the new CNS risk model in ENKTL?. <i>Blood</i> , 2020, 136, 2486-2487.	0.6	0
263	Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).. <i>Journal of Clinical Oncology</i> , 2021, 39, 2640-2640.	0.8	0
264	HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S371.	0.2	0
265	TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S411.	0.2	0
266	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. <i>Blood</i> , 2006, 108, 2739-2739.	0.6	0
267	Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.. <i>Blood</i> , 2007, 110, 1563-1563.	0.6	0
268	Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner. <i>Blood</i> , 2008, 112, 804-804.	0.6	0
269	MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.. <i>Blood</i> , 2009, 114, 1100-1100.	0.6	0
270	Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. <i>Blood</i> , 2010, 116, 1803-1803.	0.6	0

#	ARTICLE	IF	CITATIONS
271	CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. <i>Blood</i> , 2011, 118, 427-427.	0.6	0
272	Chemoresistance Can Be Reliably Overcome with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT/ASCT) for Relapsed and Refractory Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 2022-2022.	0.6	0
273	Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era. <i>Blood</i> , 2012, 120, 1602-1602.	0.6	0
274	Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8552-8552.	0.8	0
275	Outcome and prognostic factors in BRAF mutation positive metastatic melanoma treated with a BRAF inhibitor: A population-based study in British Columbia.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20045-e20045.	0.8	0
276	Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC). <i>Blood</i> , 2013, 122, 4369-4369.	0.6	0
277	The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience. <i>Blood</i> , 2013, 122, 4390-4390.	0.6	0
278	The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 1804-1804.	0.6	0
279	Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 136-136.	0.6	0
280	Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience. <i>Blood</i> , 2014, 124, 3076-3076.	0.6	0
281	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2015, 126, 3950-3950.	0.6	0
282	Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression. <i>Blood</i> , 2015, 126, 2737-2737.	0.6	0
283	Genetic Alterations of G13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 111-111.	0.6	0
284	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 920-920.	0.6	0
285	Outcome of Hodgkin Lymphoma after Progression Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2994-2994.	0.6	0
286	Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia. <i>Blood</i> , 2016, 128, 5852-5852.	0.6	0
287	Validation of a Simplified International Prognostic Score (IPS-3) in Patients with Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2916-2916.	0.6	0
288	Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 1699-1699.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL): Long Term Outcomes and Secondary Malignancies in 673 Patients Treated in British Columbia (BC). <i>Blood</i> , 2019, 134, 4300-4300.	0.6	0
290	Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2763-2763.	0.6	0
291	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019, 134, 4026-4026.	0.6	0
292	Impact of Disease Extent and Distribution on Outcomes in Stage II Follicular Lymphoma Treated with Curative-Intent Radiation Therapy. <i>Blood</i> , 2021, 138, 2431-2431.	0.6	0
293	Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis. <i>Blood</i> , 2021, 138, 1353-1353.	0.6	0
294	A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication. <i>Blood</i> , 2021, 138, 50-50.	0.6	0
295	Single-Cell Profiling Reveals Clinically Relevant Evolutionary Trajectories and Alternate Biologies in Human Follicular Lymphoma. <i>Blood</i> , 2021, 138, 450-450.	0.6	0
296	Hodgkin Variant of Richter's Transformation (HvRT) Among Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC), Canada. <i>Blood</i> , 2020, 136, 13-15.	0.6	0
297	Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 18-19.	0.6	0
298	Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC). <i>Blood</i> , 2020, 136, 33-34.	0.6	0
299	Management of Patients with Peripheral T-Cell Lymphoma. , 0, , 352-364.		0
300	Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	0
301	Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2739-2742.	0.6	0